Previous 10 |
ALAMEDA, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on AgeX Therapeutics, Inc. (AgeX) (NYSE American: AGE) and BioT...
HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Friday, LD Micro reinstituted their nearly 1000 company index of micro-caps, with the belief that our industry needs a truly accurate indicator of what is going on in the micro-cap world. We took the opportunity to put a microscope on these mi...
Co-Diagnostics (NASDAQ: CODX ) +176% on eliminating debt . More news on: Co-Diagnostics, Eyenovia, Inc., Ekso Bionics Holdings, Inc., Stocks on the move, , Read more ...
ALAMEDA, Calif., Jan. 30, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its affiliate company, OncoCyte Corporation (OncoCyte) (OCX) , a developer of novel, non-invasive tests...
News, Short Squeeze, Breakout and More Instantly...
Brooklyn ImmunoTherapeutics Inc. Company Name:
BTX Stock Symbol:
NYSE Market:
Brooklyn ImmunoTherapeutics Inc. Website:
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s...
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnos...
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today ann...